Daiichi Sankyo Company, Limited Share Price Other OTC
Equities
DSNKY
US23381D1028
Pharmaceuticals
Sales 2024 | 1,602B 10.29B 859B | Sales 2025 * | 1,767B 11.34B 947B | Capitalization | 9,964B 63.99B 5,342B |
---|---|---|---|---|---|
Net income 2024 | 201B 1.29B 108B | Net income 2025 * | 191B 1.23B 102B | EV / Sales 2024 | 5.72 x |
Net cash position 2024 * | 556B 3.57B 298B | Net cash position 2025 * | 629B 4.04B 337B | EV / Sales 2025 * | 5.28 x |
P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
50.3
x | Employees | - |
Yield 2024 |
1.05% | Yield 2025 * |
1.13% | Free-Float | 97.04% |
Latest transcript on Daiichi Sankyo Company, Limited
Managers | Title | Age | Since |
---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01/07/01 |
Hiroyuki Okuzawa
PSD | President | 61 | 01/17/01 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 01/19/01 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 01/19/01 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01/07/01 |
1st Jan change | Capi. | |
---|---|---|
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |